胸腹主动脉瘤修复术后长期死亡与并发症的危险因素
基于加拿大安大略省2006至2017年664例胸腹主动脉瘤修复患者的人群研究,比较其与匹配对照的生存率,并分析长期死亡及复合并发症(TALE)的危险因素。结果显示修复组5年及8年生存率均显著低于对照人群,急诊手术是最强危险因素,修复方式(腔内vs开放)与远期结局无关。
要点
- 胸腹主动脉瘤修复后5年生存率55.0%,8年44.6%,均显著低于匹配对照人群。
- 急诊手术是远期死亡和TALE的最强危险因素(死亡HR 2.27)。
- 既往冠脉血运重建和高流量中心治疗与更好远期结局相关。
核心结论
- 胸腹主动脉瘤修复后长期生存率低于一般人群,且与治疗方式无关。
- 急诊或紧急修复是远期不良事件的最强危险因素。
- 既往冠脉血运重建和高流量中心治疗与改善的远期结局相关。
研究设计与样本
- 基于加拿大安大略省2006至2017年的人群研究,纳入664例接受胸腹主动脉瘤修复的成人(平均年龄69.3±10.6岁,71%为男性)。
- 采用Cox hazards模型(含医院随机效应)分析基线危险因素与修复后死亡及并发症的关联。
- 将修复患者与无胸腹主动脉瘤的对照按年龄、性别、居住区域和平均年家庭收入匹配比较生存率。
主要发现
- 修复组5年和8年生存率分别为55.0%(95%CI 49.8%-60.1%)和44.6%(95%CI 40.4%-49.6%),对照组分别为85.6%(95%CI 83.9%-87.1%)和76.3%(95%CI 73.8%-78.8%),HR 1.97(95%CI 1.67-2.32,P<.01)。
- 修复组5年和8年无TALE生存率分别为49.2%(95%CI 44.7%-53.7%)和37.3%(95%CI 33.1%-42.4%)。
- 随访期死亡危险因素包括年龄增长(每5岁HR 1.21,95%CI 1.13-1.28)、外周动脉疾病(HR 1.46,95%CI 1.03-2.09)、高血压(HR 1.58,95%CI 1.03-2.43)、充血性心力衰竭(HR 1.78,95%CI 1.34-2.36)和急诊手术(HR 2.27,95%CI 1.74-3.00)。
- 既往冠脉血运重建(HR 0.63,95%CI 0.41-0.96)和高流量中心治疗(研究期间>60例TAAA修复,HR 0.71,95%CI 0.55-0.91)与较低死亡率相关。
- 年龄增长、慢性肾病、充血性心力衰竭和急诊手术与较高TALE发生率相关;修复方式(腔内vs开放)与死亡或TALE无关。
临床怎么用
- 对胸腹主动脉瘤修复患者应重视长期随访,尤其合并高龄、外周动脉疾病、高血压、心力衰竭或慢性肾病者。
- 急诊手术患者远期不良事件风险最高,应加强术后监测和风险管理。
- 既往冠脉血运重建可能提示更好远期结局,高流量中心治疗与改善结局相关,可作为转诊参考。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: We sought to determine the risk factors associated with late mortality or complications (thoracoabdominal aortic aneurysm [TAAA] life-altering events [TALE]: a composite of mortality, permanent paraplegia, permanent dialysis, and stroke) for patients who had undergone endovascular or open TAAA repair. METHODS: We performed a population-based study of patients who had undergone TAAA repair in Ontario, Canada, from 2006 to 2017. The association of baseline risk factors with mortality and complications after repair was examined using Cox hazards models with hospital-specific random effects. The survival of patients who had undergone TAAA repair was compared with that of controls without TAAAs. The two groups were matched by age, sex, area of residence, and average annual household income. The type of repair (endovascular vs open) was included in all models. RESULTS: We identified 664 adults (mean age, 69.3 ± 10.6 years; 71% men) who had undergone TAAA repair. At 5 and 8 years, survival was 55.0% (95% confidence interval [CI], 49.8%-60.1%) and 44.6% (95% CI, 40.4%-49.6%) for patients who had undergone TAAA repair vs 85.6% (95% CI, 83.9%-87.1%) and 76.3% (95% CI, 73.8%-78.8%) for the control population, respectively (hazard ratio [HR], 1.97; 95% CI, 1.67-2.32; P < .01). For the TAAA group, freedom from TALE was 49.2% (95% CI, 44.7%-53.7%) and 37.3% (95% CI, 33.1%-42.4%) at 5 and 8 years of follow-up, respectively. On multivariable analysis, the risk factors associated with mortality during follow-up included older age (HR, 1.21 per 5-year increase; 95% CI, 1.13-1.28), peripheral artery disease (HR, 1.46; 95% CI, 1.03-2.09), hypertension (HR, 1.58; 95% CI, 1.03-2.43), congestive heart failure (HR, 1.78; 95% CI, 1.34-2.36), and urgent procedures (HR, 2.27; 95% CI, 1.74-3.00). A lower rate of death was observed for those with previous coronary revascularization (HR, 0.63; 95% CI, 0.41-0.96) and those who had undergone repair at high-volume institutions (>60 TAAA repairs during the study period; HR, 0.71; 95% CI, 0.55-0.91). Older age, chronic kidney disease, congestive heart failure, and urgent procedures were associated with a higher rate of TALE. The type of repair (endovascular vs open) was not associated with mortality or TALE. CONCLUSIONS: TAAA repair was associated with reduced long-term survival compared with the general population, regardless of the mode of treatment. Urgent or emergent repair was the most profound risk factor for late adverse events. The type of repair (endovascular vs open) was not a predictor of long-term death or complications. Previous coronary revascularization and treatment performed at a high-volume institution were associated with improved late outcomes for patients undergoing TAAA repair.
引用
- Rocha RV, Lindsay TF, Nasir D, et al. Risk factors associated with long-term mortality and complications after thoracoabdominal aortic aneurysm repair. J Vasc Surg. 2021. PMID: 34606954. doi:10.1016/j.jvs.2021.09.021
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。